Interview with Children’s Hospital of Philadelphia

29/04/2020

The following interview is part of our interview series that we are conducting with Key Opinion Leaders, Experts and Business Managers within the HLA field. This time, Carol Kneibb and Ryan Morlen from Children’s Hospital of Philadelphia talk about their experiences and thoughts on HLA laboratory activities. We hope...

The Complex Immunological Pathogenesis Behind COVID-19

27/04/2020

Clinicians, scientific communities, biotech companies, public health agencies alongside with governments around the world are working to support the fight against the current COVID19 pandemic. Despite these huge efforts, we do not have a detailed picture of the new coronavirus, including the immunopathogenesis of the disease. This review tries...

Webinar – What are the crucial factors to perform a successful NGS run?

23/04/2020

Join us for a Webinar on Tuesday, April 27 with Libor Kolesár (Senior Field Application Scientist, Omixon) who will be talking about the common causes of NGS library preparation, sequencing of Holotype HLA and how to troubleshoot them. Agenda: 🔸 Very low library concentration 🔸 Overloading...

Omixon Academy 2020 – HLA (Human Leukocyte Antigen) and its Basic Immunological Roles

22/04/2020

During the COVID-19 pandemic, Omixon is committed to continuously provide resources and educational material to the HLA community. We have compiled a list of topics that both beginners and advanced users could find beneficial. This time, Omixon invites you to join our next educational session to learn more about HLA (Human...

Omixon Founder, Attila Bérces Returns as CEO, Aims to Roll-Out New Products

20/04/2020

We are happy to announce that Omixon’s founder and chairman Dr. Attila Bérces returns as CEO. Outgoing CEO Dr. Peter Meintjes led the early commercialization of Omixon’s flagship product Holotype HLA since 2014 before stepping into the CEO role in 2017. In concert between the incoming and outgoing CEOs,...